Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypercoagulability: too many tests, too much conflicting data.

Kenneth A Bauer1, Frits R Rosendaal, John A Heit

  • 1VA Medical Center, Roxbury, MA 02132, USA.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Current and future therapeutic options for COVID-19].

Nederlands tijdschrift voor geneeskunde·2022
Same author

Change in Hematoma Size after Dexamethasone Therapy in Chronic Subdural Hematoma Subtypes: A Prospective Study in Symptomatic Patients.

Journal of neurotrauma·2022
Same author

Reference intervals of urinary kidney injury biomarkers for middle-aged men and women determined by quantitative protein mass spectrometry.

Annals of clinical biochemistry·2022
Same author

Opioid prescribing patterns after arthroplasty of the knee and hip: a Dutch nationwide cohort study from 2013 to 2018.

Acta orthopaedica·2022
Same author

Valid Evidence for Diagnosis and Treatment of Infections in the Intensive Care Unit: Beyond Randomized Control Trial Study Design (Trial Emulation and Machine Learning).

Journal of clinical medicine·2022
Same author

Association between prescription opioid use and unplanned intensive care unit admission and mortality in the adult population of the Netherlands: a registry study.

British journal of anaesthesia·2022
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Identifying hereditary and acquired risk factors for venous thrombotic events is possible. However, clinical management decisions are complicated by uncertainty regarding the impact of genetic testing on patient outcomes.

Area of Science:

  • Hematology
  • Genetics
  • Clinical Medicine

Background:

  • Venous thrombotic events (VTE) have identifiable hereditary and acquired risk factors.
  • Clinicians face numerous laboratory tests for VTE patients, leading to uncertainty in management.
  • Widespread genetic testing for prothrombotic abnormalities is debated due to limited data on improved clinical outcomes.

Observation:

  • Epidemiology of VTE emphasizes hereditary and acquired risk factors.
  • Case-control and family studies provide insights into thrombosis risk.
  • Management strategies for hereditary thrombophilia and high-risk procedures are proposed.

Findings:

  • Laboratory test results significantly impact clinical decision-making in VTE management.
  • Assessing recurrence risk and balancing anticoagulation benefits against bleeding risk complicates management.

Related Experiment Videos

  • Case presentations illustrate the practical application of laboratory findings.

    • Implications:

    • Further research is needed to clarify the clinical utility of genetic testing in VTE.
    • Standardized guidelines are required for interpreting and applying laboratory results in VTE patient care.
    • Improved understanding of risk factors can refine personalized treatment strategies for VTE.